Characteristics of lower respiratory tract microbiota in the patients with post-hematopoietic stem cell transplantation pneumonia

Yukun He¹, Jia Li¹, Wenyi Yu¹, Yali Zheng¹,², Donghong Yang¹, Yu Xu¹, Lili Zhao¹, Xinqian Ma¹, Pihua Gong¹* and Zhancheng Gao¹*

¹Department of Respiratory and Critical Care Medicine, Peking University People’s Hospital, Beijing, China. ²Department of Respiratory, Critical Care, and Sleep Medicine, Xiang’ian Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China

Background: Pneumonia is a leading cause of non-relapse mortality after hematopoietic stem cell transplantation (HSCT), and the lower respiratory tract (LRT) microbiome has been proven to be associated with various respiratory diseases. However, little is known about the characteristics of the LRT microbiome in patients with post-HSCT compared to healthy controls (HC) and community-acquired pneumonia (CAP).

Methods: Bronchoalveolar lavage samples from 55 patients with post-HSCT pneumonia, 44 patients with CAP, and 30 healthy volunteers were used to detect microbiota using 16S rRNA gene sequencing.

Results: The diversity of the LRT microbiome significantly decreased in patients with post-HSCT pneumonia, and the overall community was different from the CAP and HC groups. At the phylum level, post-HSCT pneumonia samples had a high abundance of Actinobacteria and a relatively low abundance of Bacteroidetes. The same is true for non-survivors compared with survivors in patients with post-HSCT pneumonia. At the genus level, the abundances of Pseudomonas, Acinetobacter, Burkholderia, and Mycobacterium were prominent in the pneumonia group after HSCT. On the other hand, gut-associated bacteria, Enterococcus were more abundant in the non-survivors. Some pathways concerning amino acid and lipid metabolism were predicted to be altered in patients with post-HSCT pneumonia.

Conclusions: Our results reveal that the LRT microbiome in patients with post-HSCT pneumonia differs from CAP patients and healthy controls, which could...
be associated with the outcome. The LRT microbiota could be a target for intervention during post-HSCT pneumonia.

KEYWORDS
hematopoietic stem cell transplantation, pneumonia, bronchoalveolar lavage, lower respiratory tract, microbiome

Introduction

Hematopoietic stem cell transplantation (HSCT) is a potentially curative method of treating hematologic and lymphoid malignancies (Harris et al., 2016). Overall survival following HSCT has significantly improved due to advances in transplant management (Gooley et al., 2010). The success of allogeneic HSCT, however, is hindered by certain complications (Bergeron and Cheng, 2017). Of all the organ-specific complications that can occur after HSCT, pneumonia is more complicated and difficult to treat and has been reported in 30–60% of HSCT recipients (Kader et al., 1994; Kotloff et al., 2004; Peters and Afessa, 2005; Lucena et al., 2014). Pneumonia, including community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), can occur early or late after the procedure, including during the pre-engraftment (neutropenic) phase and the early and late post-engraftment phases (Chi et al., 2013; Ahya, 2017; Bondeelle and Bergeron, 2019). Despite advances in posttransplant prevention support care, pneumonia remains a leading cause of non-relapse mortality after HSCT (Nusair et al., 2004; Choi et al., 2014; Harris et al., 2016; Zinter and Hume, 2021), which collectively shape the respiratory microbiome. While the importance of the lung microbiome has already been proposed in the context of HSCT recipients with post-HSCT PCs (O’Dwyer et al., 2018), the characteristics of lung microbiota in HSCT recipients with pneumonia were less reported due to the complex conditions after HSCT. Moreover, the differences in lung microbiota related to the outcomes were undetermined. Therefore, we hypothesize that patients with post-HSCT pneumonia possessed lung microbiota that differs from that of healthy control subjects and CAP patients with normal immune function and lung microbiota could be differed in different clinical outcomes of patients with post-HSCT pneumonia.

To clarify the composition and putative function of the lung microbiota of patients with post-HSCT pneumonia, we applied 16S ribosomal ribonucleic acid (rRNA) gene sequencing to bronchoalveolar lavage fluid (BALF) samples from 55 patients with post-HSCT PCs, 44 patients with CAP, and 30 healthy control subjects (HCs).

Materials and methods

Study population

This study received ethics approval from the Ethical Review Committee of Peking University People’s Hospital (No. 2016PHB202-01). The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to clinical data collection and sampling.

A retrospective analysis was conducted for 55 patients with post-HSCT pneumonia (including CAP and HAP). Among
them, patients who died after treatment were defined as non-survivors. Additionally, 30 healthy volunteers from the medical center were enrolled in the HC group voluntarily, and 44 immunocompetent CAP patients were recruited as disease control subjects. All participants were enrolled from Peking University People’s Hospital between April 2014 and August 2017. CAP and HAP were defined according to the published standards (Mandell et al., 2007; Kalil et al., 2016; Cao et al., 2018). Subjects with other pulmonary diseases, or tumors were excluded, and healthy volunteers taking antibiotics or hormones for the last three months were excluded (Charlson et al., 2011). General participant demographics, including age, gender, complications, laboratory findings, and clinical treatments, were collected from medical record system using a standard form. BALF was detected for routine microbiological examination, including routine culture, virus quantity polymerase chain reaction (qPCR), GeneXpert, 1,3-β-D glucan test, and galactomannan test. Baseline characteristics and clinical indicators of patients were listed in Table 1 and e-Tables 1-3.

Sample preparation, DNA extraction, and sequencing

For patients diagnosed with pneumonia, bronchoscopy was performed as a part of clinical management within 72 h after hospital admission before the ventilation treatments. Detailed sampling procedures, pretreatment, and storage were performed as described in previous studies (Zheng et al., 2019; He et al., 2022). Sampling controls were collected through simulated bronchoscopy procedures (no patient) using the same instrument and method. BALF was then centrifuged. Total DNA was extracted from the BALF precipitate and 500 µL of the supernatant using the CTAB/SDS method. 16S rRNA genes of the V3-V4 region were amplified with pre-validated primers (Klindworth et al., 2013). Detailed procedure of library construction was provided in the supplementary materials. High-quality libraries were sequenced to 250 bp paired-end raw reads on the HiSeq2500 platform. The V3-V4 regions were not amplified in the sampling control. Besides, contaminants were excluded from this analysis using negative controls containing only sterile ddH₂O and reagents for extraction and PCR amplification. “Decontam” R package was applied to further reduce the potential impact of contamination for low biomass samples using the prevalence method in the “isNotContaminant” function with thresholds at 0.1 (Davis et al., 2018; Karstens et al., 2019) (e-Table 4). While all the steps of sampling, DNA extraction and PCR amplification were controlled with negative reagents, further analysis was performed to ensure that the potential risks of contamination were minimized. The results of this study were compared with the 92 contamination genera detected in the negative sequencing

### Table 1: Baseline characteristics and clinical indicators of patients with post-HSCT pneumonia, CAP patients, and health control subjects.

|                          | post-HSCT pneumonia (N = 55) | CAP (N = 44) | HC (N = 30) | P-value |
|--------------------------|-----------------------------|-------------|------------|---------|
| **Age**                  | 34 (28-44.5)                | 53.5 (37-65.5) | 60 (47.5-63.5) | <0.001 a,b |
| **Gender, n, (% male)**  | 40 (72.7)                   | 28 (63.6)   | 11 (36.7)  | <0.001 |
| **Smokers, n (%)**       | 4 (7.3)                     | 8 (18.2)    | 0 (0)      | 0.009   |
| **Comorbidities**        |                             |             |            |         |
| **Diabetes Mellitus, n (%)** | 6 (10.9)                   | 6 (13.6)    | 3 (10.0)   | 0.234   |
| **Hypertension, n (%)**  | 15 (32.7)                   | 14 (31.8)   | 11 (36.7)  | 0.539   |
| **Laboratory Findings**  |                             |             |            |         |
| **Peripheral blood**     |                             |             |            |         |
| **WBC (× 10⁹/L)**        | 4.31 (2.80-7.00)            | 6.40 (5.13-9.73) | 6.87 (5.68-8.31) | <0.001 a,b |
| **Neutrophils (%)**      | 73.40 (59.80-86.30)         | 71.87 (63.02-83.02) | 61.60 (53.72-64.77) | <0.001 a |
| **Lymphocytes (%)**      | 16.50 (7.70-27.1)           | 15.96 (8.92-27.19) | 29.98 (24.93-36.83) | <0.001 a |
| **BAL related**          |                             |             |            |         |
| **PMN percentages (%)**  | 14.00 (2.00-28.50)          | 18.00 (1.75-65.50) | 1.00 (0.50-2.00)   | <0.001 a |
| **Lymphocyte percentages (%)** | 33.00 (17.00-53.50) | 21.00 (11.00-43.50) | 12.00 (8.00-30.75) | <0.001 a |
| **Eosinophil percentages (%)** | 0.00 (0.00-1.00)  | 0.00 (0.00-1.00)   | 0.00 (0.00-1.00)   | 0.042   |
| **Macrophages percentages (%)** | 42.00 (21.00-67.00) | 37.00 (13.50-60.00) | 86.50 (64.50-91.00) | <0.001 a |
| **Inflammatory markers**  |                             |             |            |         |
| **PCT (µg/L)**           | 0.20 (0.11-0.50)            | 0.16 (0.05-1.02) | 0.05 (0.05-0.09) | <0.001 a |
| **CRP (mg/L)**           | 30.09 (6.64-76.63)          | 40.75 (12.12-132.75) | 1.37 (0.78-2.81)   | <0.001 a |
| **ESR (mm)**             | 57.00 (27.75-89.00)         | 39.00 (19.00-61.00) | 8.50 (6.00-13.50)  | <0.001 a |
| **PSI                      | 74 (65-88)                  | 72 (51-104)   | –          | 0.235   |

a, HSCTvs.HC; b, HSCTvs.CAP; c, CAPvs.HC; HSCT hematopoietic stem cell transplantation; CAP, community-acquired pneumonia; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PCT, procalcitonin; PSI, pneumonia severity index; PMN, polymorphonuclear leukocyte; WBC, white blood cell.
within the mega-phylogeny applying the algorithm was run using 999 randomizations of the community using picante R package (Kembel et al., 2010). The nearest taxon index (NTI) and net-relatedness index (NRI) had an average relative abundance greater than 0.0002. Among the remaining 31 genera found in our data, 6 genera were not reported in samples from the respiratory tract but none had an average relative abundance greater than 0.0002.

Bioinformatics analysis

The high-quality sequencing data was generated by removing low-quality reads (the quality control rate is less than 1%), primers, barcodes, and dereplication using VSEARCH (Rognes et al., 2016). After removing the chimeric sequences with the UCHIME algorithm (Edgar et al., 2011), effective reads were obtained and denoised to generate amplicon sequence variants (ASVs) using unoise3 (Edgar, 2016). Taxonomy assignment was performed on ASVs based on the GreenGene database (DeSantis et al., 2006). The microbiome phenotypes were predicted by BugBase based on GreenGene annotation (Ward et al., 2017). PICRUSt2 was used to identify the predicted associated pathways from the inferred metagenomes of taxa with the ‘stratified’ mode (Douglas et al., 2020).

Statistical analysis

The abundance-based coverage estimator (ACE) index and Shannon index were calculated to evaluate alpha diversity using rarefied data using vegan R package (Jari Oksanen et al., 2020). The nearest taxon index (NTI) and net-relatedness index (NRI) were applied to estimate phylogenetic structure of the community using picante R package (Kembel et al., 2010). The algorithm was run using 999 randomizations of the community within the mega-phylogeny applying the “taxa.labels”. Beta diversity was assessed by permutational multivariate analysis of variance (PERMANOVA) test, and visualized using principal coordinate analysis (PCoA). Adonis test was conducted based on Bray-Curtis distances and Jaccard distances. ASV abundances were centered with log-ratio transformation prior to analysis. Differential bacterial taxa among groups were assessed using the edgeR R package based on centered log-ratio-transformed genome relative abundance (Robinson et al., 2010). A multifactorial design within the edgeR package was used to adjust confounding factors, such as age, gender, and smoking. Statistically significant genera differences (LDA > 2, P < 0.05) associated with different groups were explored using linear discriminant analysis (LDA) effect size (LEfSe) (Segata et al., 2011). Spearman’s rho was calculated using the ‘corr.test’ function within the R package. Network analysis was performed based on read count data at the genus level using SpeciEasi (Kurtz et al., 2015). The density of the networks was calculated by the “graph.density” function in the igraph R package.

For clinical indicators, all categorical variables are presented as numbers (percentages), parametric continuous variables are presented as the mean ± SD, and nonparametric continuous variables are presented as median and interquartile ranges (25th and 75th percentiles). Student’s t-test or analysis of variance (ANOVA) with post hoc Tukey HSD test were used to analyze continuous parametric data. Continuous nonparametric data were analyzed using Mann–Whitney U or a Kruskal–Wallis test. All categorical data were analyzed using a chi-square or Fisher’s exact test. All tests were two-sided, p-values were corrected using Benjamin–Hochberg false discovery rate (FDR), and p < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 23 software.

Results

Clinical characteristics of the study population

To explore the clinical characteristics of post-HSCT pneumonia, we summarized clinical information from 55 subjects. For HSCT patients with pneumonia, the median age was 34 years old, and 72.7% of them were male. A total of 47.3% of patients underwent transplantation for acute myelocytic leukemia (AML). e-Table 1 showed that 18 (32.7%) patients died. Pneumonia occurred at late post-engraftment phases in 35 (63.6%) patients, and occurred at pre-engraftment (neutropenic) phase in 4 (7.3%) patients (e-Table 1). The median time from transplant to the onset of pneumonia was 165 days. The PMN levels, and the percentage of polymorphonuclear leukocytes (PMNs) in the BALF were significantly elevated in non-survivors (e-Table 2), suggesting that exacerbated inflammation may result in poor outcomes in patients with post-HSCT pneumonia.

Demographic information on the three groups is displayed in Table 1, along with comorbidities, blood cell counts, BALF cell counts, inflammatory markers, and the pneumonia severity index (PSI). Neutrophil percentage, C-reactive protein (CRP), procalcitonin (PCT) and erythrocyte sedimentation rate (ESR) levels, and the percentage of polymorphonuclear leukocytes (PMNs) in the BALF were higher in patients with pneumonia than in the HC group. In contrast, the lymphocyte percentage in the peripheral blood and the macrophage percentage in the BALF were significantly lower. Pathogens were detected in 47.3% of BALF samples with conventional hospital-based microbiology tests in patients with post-HSCT pneumonia and 65.9% in patients with CAP (e-Table 3). 89.1%, 81.8%, and 54.5% patients with post-HSCT pneumonia received the antibiotics, antifungals, and Pneumocystis carinii prophylaxis,
respectively (e-Table 3). Moreover, there was no difference in the proportion of patients taking antibiotics in the last three months between the two diseased groups (e-Table 3), and the mortality is higher in the post-HSCT pneumonia group.

**Disturbance of the LRT microbiome**

Species accumulation curves and the read counts of samples revealed that the sequencing was sufficient to describe associated microbial community (e-Figure 1; e-Table 6). After filtering for sequence variants in at least two samples with a minimum relative abundance of 0.05% (Bowerman et al., 2020), 2396 sequence variants were retained for community analysis. In terms of alpha diversity, no significant differences were observed in the ACE index, whereas the Shannon index showed significant decreases in diversity in patients with post-HSCT pneumonia compared to the HC and CAP groups (Figures 1A, B). The mean values of NTI and NRI in all groups was greater than 0, indicating the samples clustering in each group (Figures 1C, D). The NTI values in samples with post-HSCT pneumonia were less positive compared to the CAP and HC samples, which indicated that phylogenetic clustering was weakest in the post-HSCT pneumonia samples. The PERMANOVA test demonstrated that the bacterial community of the post-HSCT pneumonia group significantly differs from that of the CAP or HC group (Figure 1E). The Adonis tests based on Bray-Curtis distances and Jaccard distances revealed that significant differences existed in both composition and abundance of tax among groups (Figures 1F, G). Besides, we found no significant difference in the microbiota composition in terms of smoking status ($p = 0.297$) in all subjects and in the HC group, there is no difference in sex ($p = 0.19$), age ($p = 0.052$) or comorbidity groups. Similarly, antibiotic usage ($p = 0.278$) or corticosteroid usage ($p = 0.552$) had no effect in the microbiota composition of patients (e-Figures 2A–G). These results indicate that patients with post-HSCT pneumonia had decreased diversity and have a different LRT microbiome composition compared with the HC or CAP group.

To determine specific bacterial taxa correlated with patients with post-HSCT pneumonia, we compared the relative
abundances (RA) of microbiota among groups. As shown in Figure 2A, the five most abundant phyla included Proteobacteria, Firmicutes, Bacteroidetes, Fusobacteria, and Actinobacteria. Specifically, post-HSCT pneumonia samples had a higher RA of Actinobacteria and a relatively low RA of Fusobacteria and Bacteroidetes. The top 30 genera in RA were shown in Figure 2B. Obviously, the RA of Sphingomonas, Prevotella, and Bifidobacterium were significantly increased. According to the Lefse analysis, the RA of Pseudomonas, Acinetobacter, Burkholderia, and Mycobacterium were prominent in the pneumonia group after HSCT (Figure 2C).

Potential function of the LRT microbiome

Predicted phenotypes based on taxonomic classification were analyzed with BugBase, which indicated that aerobic bacteria were more abundant in patients with post-HSCT pneumonia than in the CAP and HC groups, while the abundance of anaerobic bacteria was the opposite (e-Figures 3A, B, p < 0.05). Additionally, the results suggested that Gram-positive bacteria were more abundant in both post-HSCT pneumonia and CAP groups than in the HC group, while the abundance of Gram-negative bacteria was lower (e-Figures 3C, D, p < 0.05).

To explore differences in potential function, we annotated the 16S reads using PICRUSt2 based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et al., 2021), and obtained 193 KEGG pathways. Through a Wilcoxon Rank Sum Test, we found that 99 and 107 pathways may be differentially expressed in the post-HSCT pneumonia group compared with CAP and HC groups, respectively (e-Tables 9, 10). The expression of multiple pathways concerning amino acid metabolism, such as arginine, histidine, and tyrosine, was elevated in patients with post-HSCT pneumonia compared to the two control groups (Figure 3A). The pathways “biosynthesis of unsaturated fatty acids” and “pyruvate metabolism” were predicted to be more enriched in patients with post-HSCT pneumonia (Figure 3B). Compared with the HC group, pathways associated with “cytokine-cytokine receptor interaction” were more abundant in patients with post-HSCT pneumonia, but the predicted “NOD-like receptor signaling” pathway decreased (Figure 3B). These results suggest that the
predicted microbial functions of amino acids, lipid metabolism, and inflammatory reactions may change in the patients with post-HSCT pneumonia.

**The LRT microbiome in non-survivors**

To explore the structure of the flora in patients with post-HSCT pneumonia, we compared subgroups within the 55 samples. No significant difference was observed in microbiota composition or diversity in terms of pathogen detection (e-Figure 4) or post-HSCT period (neutropenic phase, early and late post-engraftment phase, e-Figure 5) or outcome (survivors vs. non-survivors) (Figures 4A, B). However, a higher RA of Actinobacteria and a lower RA of Bacteroidetes were found in non-survivors (e-Figure 6), and 45 genera were identified as differential taxa between survivors and non-survivors (e-Table 11). The RAs of the genera Enterococcus, Acinetobacter, Burkholderia, Mycobacterium, and Escherichia all significantly increased in non-survivors, while the RAs of the genera Neisseria, Bacillus, and Veillonella decreased in non-survivors (Figure 4C). Among them, the RA of Enterococcus was positively correlated with PCT levels, and Mycobacterium was positively correlated with PMN percentage in the BALF numerically (Figure 4D; e-Table 12). The RA of Veillonella was negatively correlated with the neutrophil percentage. Through phenotype prediction, potentially pathogenic and aerobic bacteria were enriched in non-survivors (e-Figure 7, all \( p < 0.05 \)).

**Discussion**

The LRT microbiota is crucial for the host immune system, and the imbalance between microbial migration and removal is correlated with alveolar and systematic inflammation (O’Dwyer et al., 2016). Understanding the composition of the LRT microbiota under different diseases is essential for identifying potential mechanisms underlying the pathogenesis of post-
HSCT pneumonia and could offer crucial insights into therapeutic targets. Although sputum sample is noninvasive and was used to explore the microbiome in diverse pulmonary diseases, it is difficult to collect for some patients and all healthy controls. Besides, the location of the respiratory tract represented by the sputum sample cannot be determined and sputum sample is highly likely to be contaminated by the oral microbiota. On the contrary, BALF has been believed to be a viable option for the lung microbiome (Cheng et al., 2020). Thus, in this study, we characterized the LRT microbiome of 55 patients with post-HSCT pneumonia and provided evidence for significant alterations in the bacterial community, utilizing the remaining BALF samples from clinical testing.

Previous studies have found that intestinal microbiota and dental biofilm microbiota dysbiosis occurred during HSCT, marked by a gradual loss of bacterial diversity (Heidrich et al., 2021). Our results also showed a significantly decreased alpha diversity in patients with post-HSCT pneumonia compared to the CAP and HC groups. The composition of the LRT microbiome in post-HSCT pneumonia patients was characterized by a decreased abundance of commensal genera and an overgrowth of opportunistic pathogens, such as Acinetobacter (Du et al., 2021) and Mycobacterium (Meehan et al., 2021). Thus, under the state of immune defects and chronic inflammation, the bacterial community was likely to be seriously altered in patients after HSCT, which elicited epithelial and luminal inflammation, which may further alter the conditions in the lung microenvironment, perpetuating dysbiosis and increasing the susceptibility to infection. However, although Nearing et al. reported that edgeR and LEfSe often identified the most significant differential ASVs than any other tools, they have relatively high false discovery rate (Nearing et al., 2022).

According to the predicted phenotypes, the abundance of anaerobic bacteria decreased in patients with post-HSCT pneumonia, and at the phylum level, a relatively low abundance of Bacteroidetes was observed compared with the HC group. The same results were also observed in non-survivors of the post-HSCT pneumonia group compared to the survivors. Marsland et al. reported that Bacteroidetes are strictly anaerobic and that most Bacteroidetes are sensitive to low pH (Marsland and Gollwitzer, 2014). Robustly disturbed and reduced anaerobic bacteria could be caused by chemotherapy, antibiotics, mechanical ventilation, or HSCT itself, and inflammatory response could lower the local PH in

![Figure 4](image-url)

**FIGURE 4** Differences in lung microbial composition between survivors and non-survivors of post HSCT pneumonia patients (A) Comparison of Chao1, ACE, Shannon and Simpson diversity index in different groups for assessment of microbiome alpha diversity of survivors and non-survivors. ns, no significant differences were observed between the groups. (B) Beta diversity was assessed by PERMANOVA test based on Jaccard distances using principal coordinate analysis (PCoA) ($p = 0.361$). (C) Differential genera between survivors and non-survivors using edgeR package. CPM, counts per million. (D) Spearman’s rho calculated between ASVs and clinical indicators. Black stars within heatmap boxes indicate significant results ($p < 0.05$), Benjamini–Hochberg adjustment for multiple comparisons. ASV abundances were centered with log-ratio transformation prior to analysis.
Despite the efforts made in contamination control, the potential absolute abundances of microorganisms are needed. Lastly, were described, meaning that further research to detection of resolution is lower, and only relative abundances of species should be further explored using animal models. Third, the 16s development of post-HSCT pneumonia is uncertain, which the observed alterations in the LRT microbiome and the effects of each variability. Second, the causal relationship between explore lung microbiome characteristics in this population and the HC group is unclear. Therefore, further experiment is needed to lung microbiome between the post-HSCT pneumonia group and a variety of factors. Thus, the direct cause of the differences in the microbiome in the post-HSCT pneumonia group was shaped by corticosteroids and cytotoxic drugs inevitably, so the lung recipients were received therapy such as antibiotics, methods, and transplant types). Meanwhile, nearly all HSCT pneumonia (including the primary disease, pretreatment products to distant organs in non-survivors, which should be investigated further using paired gut and lung specimens.

There are some limitations to our study. First, clinical heterogeneity is a major concern in patients with post-HSCT pneumonia (including the primary disease, pretreatment methods, and transplant types). Meanwhile, nearly all HSCT recipients were received therapy such as antibiotics, corticosteroids and cytotoxic drugs inevitably, so the lung microbiome in the post-HSCT pneumonia group was shaped by a variety of factors. Thus, the direct cause of the differences in the lung microbiome between the post-HSCT pneumonia group and HC group is unclear. Therefore, further experiment is needed to explore lung microbiome characteristics in this population and the effects of each variability. Second, the causal relationship between the observed alterations in the LRT microbiome and the development of post-HSCT pneumonia is uncertain, which should be further explored using animal models. Third, the 16s resolution is lower, and only relative abundances of specific bacteria were described, meaning that further research to detection of absolute abundances of microorganisms are needed. Lastly, despite the efforts made in contamination control, the potential sources of oral or environmental pollution may be not completely excluded.

Despite these limitations, our study explored the LRT microbiome in patients with post-HSCT pneumonia and raises some interesting questions worthy of further investigation. Our results support the findings of larger cohorts evaluating the value of the airway microbiome and its immune interactions and propose potential targets for preventing and treating pneumonia in post-HSCT patients.

Conclusions

Our results demonstrate that the LRT microbiome in post-HSCT pneumonia, which is characterized by decreases in species diversity, the enrichment of pathogens, and reduced biotic interactions, differs from CAP patients and healthy controls. The composition of the LRT microbiome is different with outcomes in patients with post-HSCT pneumonia.

Data availability statement

The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/, PRJNA791752 and PRJNA751994.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethical Review Committee of Peking University People’s Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

YH was responsible for investigation, methodology, analysis, and writing-original draft. JL was responsible for investigation, methodology, analysis. WY, YZ, DY, YX, LZ, and XM were responsible data collection, experiment and analysis. PG and ZG were responsible for investigation, methodology, provision of in-house control data, project administration, resources, supervision, funding acquisition, writing-review and editing. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No. 82000019, No. 81870010), and the
National and Provincial Key Clinical Specialty Capacity Building Project 2020 (Department of the Respiratory Medicine).

Acknowledgments

The authors wish to thank staff members of the hospital for assistance with samples and clinical data collection.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Ahyai, V. N. (2017). Noninfectious acute lung injury syndromes early after hematopoietic stem cell transplantation. Clin. Chest Med. 38 (4), 595–606. doi: 10.1016/j.ccm.2017.07.002

Bergeron, A., and Cheng, G. S. (2017). Bronchiolitis obliterans syndrome and other late pulmonary complications after allogeneic hematopoietic stem cell transplantation. Clin. Chest Med. 38 (4), 607–621. doi: 10.1016/j.ccm.2017.07.003

Bondelied, L., and Bergeron, A. (2019). Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation. Expert Rev. Respir. Med. 13 (1), 105–119. doi: 10.1080/17438493.2019.1557049

Bowerman, K. M., Rehman, S. F., Vaughan, A., Lachner, N., Budden, K. F., Kim, R. Y., et al. (2020). Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat. Commun. 11 (1), 5886. doi: 10.1038/s41467-020-19701-0

Cao, B., Huang, Y., She, D. Y., Cheng, Q. J., Fan, H., Tian, X. L., et al. (2018). Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese thoracic society, Chinese medical association. Clin. Respir. J. 12 (4), 1320–1366. doi: 10.1183/23813936.12674

Charlson, E. S., Bittenger, K., Haas, A. R., Fitzgerald, A. S., Frank, L., Yadav, A., et al. (2011). Topographical continuity of bacterial populations in the healthy human respiratory tract. Am. J. Respir. Crit. Care Med. 184 (8), 957–963. doi: 10.1164/rccm.201104-0655OC

Cheng, C., Wang, Z., Wang, J., Ding, C., Sun, C., Liu, P., et al. (2020). Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer. Transl. Lung Cancer Res. 9 (3), 693–704. doi: 10.21037/tlcr-19-398

Chi, A. K., Soubbani, A. O., White, A. C., and Miller, K. B. (2013). An update on pulmonary complications of hematopoietic stem cell transplantation. Chest 144 (6), 1913–1922. doi: 10.1378/chest.12-1708

Choi, M. H., Jung, J. I., Chung, W. D., Kim, Y. J., Lee, S. E., Han, D. H., et al. (2016). Acute pulmonary complications in patients with hematologic malignancies. Radiographics 34 (6), 1755–1768. doi: 10.1148/rg.346130107

Cole, J. R., Wang, Q., Fish, J. A., Chai, B., McGarrell, D. M., Sun, Y., et al. (2014). Ribosomal database project: data and tools for high throughput rRNA analysis. Nucleic Acids Res. 42 (Database issue), D635–D642. doi: 10.1093/nar/gkt1244

Davis, N. M., Proctor, D. M., Holmes, S. P., Relman, D. A., and Callahan, B. J. (2014). Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. Microbiome 6 (1), 226. doi: 10.1186/1756-0500-6-226

DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojes, M., Brodie, E. L., Keller, K., et al. (2006). Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl. Environ. Microbiol. 72 (7), 5096–5072. doi: 10.1128/AEM.03086-05

Dickson, R. P., Erb-Downward, J. R., Freeman, C. M., McCloskey, L., Falkowski, N. R., Huffman, G. B., et al. (2017). Bacterial topography of the healthy human lower respiratory tract. mBio 8 (1), e02287-16. doi: 10.1128/mBio.02287-16

Dickson, R. P., Erb-Downward, J. R., Martinez, F. I., and Huffman, G. B. (2016a). The microbiome and the respiratory tract. Annu. Rev. Physiol. 78, 481–504. doi: 10.1146/annurev-phy071115-102528

Dickson, R. P., Martinez, F. I., and Huffman, G. B. (2014). The role of the microbiome in exacerbations of chronic lung diseases. Lancet 384 (9944), 691–702. doi: 10.1016/S0140-6736(14)61136-3

Dickson, R. P., Schultz, M. J., van der Poll, T., Schouten, L. R., Falkowski, N. R., Luth, J. E., et al. (2020). Lung microbiota predict clinical outcomes in critically ill patients. Am. J. Respir. Crit. Care Med. 210 (5), 555–563. doi: 10.1164/rccm.202010-1487OC

Dickson, R. P., Singer, B. H., Newstead, M. W., Falkowski, N. R., Erb-Downward, J. R., Standiford, T. J., et al. (2016b). Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat. Microbiol. 1 (10), 16113. doi: 10.1038/nmicrobiol.2016.113

Douglas, G. M., Maffei, V. J., Janeveld, J. R., Yurgel, S. N., Brown, J. R., Taylor, C. M., et al. (2020). PICRUS32 for prediction of metagenome functions. Nat. Biotechnol. 38 (6), 685–688. doi: 10.1038/s41587-020-0548-6

Du, B., Shen, N., Tao, Y., Sun, S., Zhang, F., Ren, H., et al. (2021). Analysis of gut microbiota alteration and application as an auxiliary prognostic marker for sepsis in children: a pilot study. Transl. Pediatr. 10 (6), 1647–1657. doi: 10.21037/tp-21-51

Edgar, R. C. (2016). UNOISE2: Improved error-correction for illumina 16S and ITS amplicon sequencing. BioRxiv. Available at: https://www.biorxiv.org/content/10.1101/081257v1

Edgar, R. C., Haas, B. A., Clemente, J. C., Quince, C., and Knight, R. (2011). UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27 (16), 2194–2200. doi: 10.1093/bioinformatics/btr381

Golob, J. L., Pergam, S. A., Srinivasan, S., Fiessler, T. L., Liu, C., Garcia, K., et al. (2017). Stoel microbiota at neutrophil recovery is predictive for severe acute graft vs host disease after hematopoietic cell transplantation. Clin. Infect. Dis. 65 (12), 1984–1991. doi: 10.1093/cid/cix989

Gooley, T. A., Chin, J. W., Pergam, S. A., Hingorani, S., Sorror, M. L., Bockh, M., et al. (2010). Reduced mortality after allogeneic hematopoietic cell transplantation. N Engl. J. Med. 363 (22), 2091–2101. doi: 10.1056/NEJMoa1004383

Harris, B., Moranja, S. M., Littmann, E. R., Geyer, A. L., Stover, D. E., Barker, J. N., et al. (2016). Gut microbiota predict pulmonary infiltrates after allogeneic hematopoietic cell transplantation. Am. J. Respir. Crit. Care Med. 194 (4), 450–463. doi: 10.1164/rccm.201507-1491OC

Heidrich, V., Bruno, J. S., Knebel, F. H., de Molla, V. C., Miranda-Silva, W., Asprino, P. F., et al. (2021). Dental biofilm microbiota dysbiosis is associated with the risk of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Front. Immunol. 12. doi: 10.3389/fimmu.2021.692225

He, Y., Yu, W., Ning, P., Lian, Q., Zhao, L., Xie, Y., et al. (2022). Shared and specific lung microbiota with metabolic profiles in bronchial asthma lavage fluid between infectious and inflammatory respiratory diseases. J. Inflammation Res. 15, 187–198. doi: 10.2147/JIR.S42462

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2022.943317/full#supplementary-material
